Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
37.93
-1.02 (-2.62%)
Sep 2, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Revenue
Hangzhou Biotest Biotech had revenue of 125.31M CNY in the quarter ending June 30, 2026, with 8.59% growth. This brings the company's revenue in the last twelve months to 459.42M, down -7.29% year-over-year. In the year 2025, Hangzhou Biotest Biotech had annual revenue of 448.01M, down -19.91%.
Revenue (ttm)
459.42M
Revenue Growth
-7.29%
P/S Ratio
12.41
Revenue / Employee
749.45K
Employees
613
Market Cap
5.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 448.01M | -111.39M | -19.91% |
| Dec 31, 2024 | 559.40M | 117.29M | 26.53% |
| Dec 31, 2023 | 442.11M | -1.46B | -76.75% |
| Dec 31, 2022 | 1.90B | 83.07M | 4.57% |
| Dec 31, 2021 | 1.82B | 952.70M | 110.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.46B |
| Novogene | 2.28B |
| Shenzhen Weiguang Biological Products | 1.20B |
| Boji Medical Technology | 961.34M |
| R&G PharmaStudies | 939.31M |
| Beijing Konruns Pharmaceutical | 917.05M |
| Wuhan Keqian Biology Co.,Ltd | 836.28M |
| Zhejiang Ausun Pharmaceutical | 778.50M |